The Pharma Data

JANUARY 31, 2021

The Coalition for Epidemic Preparedness Innovations (CEPI) has committed to fund Clover’s S-Trimer COVID-19 vaccine candidate through licensure with a total investment of up to $328 million , a portion of which will support the global Phase 2/3 study. About Trimer-Tag© Technology. About CEPI. —- End —-.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

The Pharma Data

JANUARY 31, 2021

The Coalition for Epidemic Preparedness Innovations (CEPI) continues to support Clover’s COVID-19 vaccine candidate and will fund its development through licensure. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Vaccination 52

Vaccination Vaccine Trials Protein 52

The Pharma Data

DECEMBER 3, 2020

The Phase 1 clinical trial was funded by the Coalition for Epidemic Preparedness Innovations (CEPI). Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. About Trimer-Tag © Technology. About CEPI. About COVID-19 S-Trimer Vaccine.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

The Pharma Data

NOVEMBER 15, 2020

Peng Liang , Founder and Chief Scientific Officer of Clover and inventor of the Trimer-Tag© technology, says, “A successful vaccine that can truly modulate the course of the COVID-19 pandemic must have four essential characteristics: safety, efficacy, scalability of manufacturing, and speed.

Vaccination 52

Vaccination Vaccine Manufacturing Life Science 52